Other Income & Expense
Other Income (Expense)
Regeneron Pharmaceuticals Other Income (Expense) increased by 15.0% to $188.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 39.9%, from $313.30M to $188.30M. Over 3 years (FY 2022 to FY 2025), Other Income (Expense) shows an upward trend with a 139.8% CAGR.
Analysis
StatementIncome Statement
SectionOther Income & Expense
CategoryProfitability
SignalContext dependent
VolatilityModerate
First reportedQ1 2013
Last reportedQ1 2026Apr 29, 2026
How to read this metric
An increase suggests higher non-operating gains or lower non-operating costs, while a decrease indicates higher non-operating expenses or lower non-operating income.
Detailed definition
Represents the net total of non-operating financial activities, including interest income, interest expense, foreign cur...
Peer comparison
Standard across all public companies; peers in the medical device sector often show similar volatility due to currency fluctuations.
Metric ID:
other_income_expense_netHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $405.60M | -$30.60M | -$197.40M | -$146.70M | $286.10M | $177.90M | -$88.70M | $66.40M | -$200.00K | $174.70M | -$50.70M | $558.50M | $313.50M | $0.00 | $313.30M | $439.20M | $736.50M | $163.80M | $188.30M |
| QoQ Change | — | -107.5% | -545.1% | +25.7% | +295.0% | -37.8% | -149.9% | +174.9% | -100.3% | >999% | -129.0% | >999% | -43.9% | -100.0% | — | +40.2% | +67.7% | -77.8% | +15.0% |
| YoY Change | — | — | — | -136.2% | >999% | — | +55.1% | +145.3% | -100.1% | -1.8% | +42.8% | +741.1% | >999% | -100.0% | +717.9% | -21.4% | +134.9% | — | -39.9% |
Range-$197.40M – $736.50M
CAGR-15.7%
Avg YoY Growth>999%
Median YoY Growth+49.0%
Other Income (Expense) at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's other income (expense)?
- Regeneron Pharmaceuticals (REGN) reported other income (expense) of $188.30M in Q1 2026.
- How has Regeneron Pharmaceuticals's other income (expense) changed year-over-year?
- Regeneron Pharmaceuticals's other income (expense) decreased by 39.9% year-over-year, from $313.30M to $188.30M.
- What is the long-term trend for Regeneron Pharmaceuticals's other income (expense)?
- Over 3 years (2022 to 2025), Regeneron Pharmaceuticals's other income (expense) has grown at a 139.8% compound annual growth rate (CAGR), from $119.90M to $1.65B.
- What does other income (expense) mean?
- The net result of all income and expenses not related to core business operations.